Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea · Delayed Price · Currency is KRW 9,510.00
+50.00 (0.53%)
Jan 29, 2026, 3:30 PM KST
Oncocross Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 884.68 | 1,072 | 91.52 | 150.25 | 100 | 90 |
Other Revenue | -0 | -0 | - | - | -0 | - |
| 884.68 | 1,072 | 91.52 | 150.25 | 100 | 90 | |
Revenue Growth (YoY) | 103.05% | 1071.49% | -39.08% | 50.24% | 11.11% | - |
Cost of Revenue | 227.45 | 354.4 | 88.31 | 121.74 | 38.66 | 60.27 |
Gross Profit | 657.23 | 717.8 | 3.21 | 28.51 | 61.34 | 29.73 |
Selling, General & Admin | 5,539 | 4,563 | 3,412 | 3,636 | 4,258 | 1,746 |
Research & Development | 3,303 | 2,625 | 2,871 | 5,926 | 2,824 | 1,548 |
Amortization of Goodwill & Intangibles | 19.09 | 19.95 | 20.96 | 20.33 | 16.71 | 14.96 |
Other Operating Expenses | 211.93 | 107.61 | 96.63 | 99.84 | 63.54 | 28.57 |
Operating Expenses | 9,649 | 7,683 | 6,813 | 10,028 | 7,401 | 3,489 |
Operating Income | -8,992 | -6,965 | -6,810 | -9,999 | -7,339 | -3,459 |
Interest Expense | -216.23 | -18.79 | -38.31 | -76.49 | -5,341 | -2,337 |
Interest & Investment Income | 291.94 | 324.62 | 125.38 | 101.6 | 67.25 | 14.38 |
Currency Exchange Gain (Loss) | -2.71 | -2.17 | -6 | -3.35 | -1.21 | - |
Other Non Operating Income (Expenses) | 409.08 | 28.6 | 2,357 | -121.84 | -600.42 | 18.17 |
EBT Excluding Unusual Items | -8,510 | -6,633 | -4,372 | -10,099 | -13,215 | -5,763 |
Gain (Loss) on Sale of Investments | 204.39 | 149.39 | 265.78 | -85.56 | 68.5 | -7,056 |
Gain (Loss) on Sale of Assets | -29.65 | 0 | - | -19.19 | - | -2.11 |
Pretax Income | -8,335 | -6,483 | -4,106 | -10,204 | -13,146 | -12,821 |
Income Tax Expense | - | - | 108.26 | - | - | - |
Net Income | -8,335 | -6,483 | -4,214 | -10,204 | -13,146 | -12,821 |
Net Income to Common | -8,335 | -6,483 | -4,214 | -10,204 | -13,146 | -12,821 |
Shares Outstanding (Basic) | 12 | 10 | 9 | 9 | 5 | 5 |
Shares Outstanding (Diluted) | 12 | 10 | 9 | 9 | 5 | 5 |
Shares Change (YoY) | 15.16% | 17.49% | 1.44% | 63.74% | 0.83% | - |
EPS (Basic) | -716.67 | -619.30 | -472.98 | -1161.74 | -2450.70 | -2409.97 |
EPS (Diluted) | -716.67 | -619.30 | -473.00 | -1161.74 | -2451.00 | -2410.00 |
Free Cash Flow | -9,568 | -5,687 | -4,913 | -8,527 | -6,534 | -3,089 |
Free Cash Flow Per Share | -822.68 | -543.24 | -551.42 | -970.80 | -1218.13 | -580.68 |
Gross Margin | 74.29% | 66.95% | 3.51% | 18.98% | 61.34% | 33.04% |
Operating Margin | -1016.38% | -649.58% | -7440.64% | -6655.30% | -7339.31% | -3843.58% |
Profit Margin | -942.14% | -604.66% | -4604.70% | -6791.63% | -13146.17% | -14245.58% |
Free Cash Flow Margin | -1081.51% | -530.40% | -5368.32% | -5675.38% | -6534.38% | -3432.45% |
EBITDA | -8,381 | -6,558 | -6,372 | -9,630 | -7,082 | -3,293 |
D&A For EBITDA | 611.13 | 406.66 | 438.4 | 369.13 | 257.59 | 166.35 |
EBIT | -8,992 | -6,965 | -6,810 | -9,999 | -7,339 | -3,459 |
Advertising Expenses | - | 113.9 | 31.53 | 123.36 | 97.13 | 18.18 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.